Atara Biotherapeutics, Inc.

Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform. Its lead asset, tab-cel (tabelecleucel), is approved in Europe, the UK, and Switzerland under the name Ebvallo for certain EBV-driven diseases, while the company continues to develop tab-cel in the United States. The business is centered on translating a cell-therapy platform into off-the-shelf treatments for cancer and autoimmune disease, with commercialization dependent on regulatory approvals and partners. Atara also has a manufacturing and commercialization relationship with Pierre Fabre, which is reflected in its commercialization revenue. The company remains highly development-driven, with value tied to clinical progress, regulatory outcomes, and the ability to scale manufacturing reliably.

31,4 %

27,1 %

−6,3 %

0.82

0.82

— Atara Biotherapeutics, Inc.
%
Commercialized cell therapy70% Approved EBV T-cell therapy sold in the EEA, UK, and Switzerland under the Ebvallo brand.
Clinical-stage immunotherapy pipeline20% Development programs centered on tab-cel and related EBV-driven disease indications in the U.S.
Manufacturing and cell selection services10% Services and related revenue tied to Pierre Fabre and commercialization support activities.

Atara’s direct customers are primarily healthcare systems, hospitals, and specialist treatment centers that administer...

  • Hospitals and specialty treatment centersprimary

    Buy and administer Ebvallo/tab-cel for patients with high unmet medical need in specialized settings.

  • National payors and health authoritiesprimary

    Influence adoption by approving pricing, reimbursement, and coverage for commercial use.

  • Commercial partnerssecondary

    Support manufacturing transfer, commercialization, and market access execution for approved products.

  • Clinical investigators and trial sitessecondary

    Enable enrollment, data collection, and execution of late-stage and early-stage studies.

Atara’s commercial footprint is currently concentrated outside the United States, where Ebvallo is approved in the EEA,...

  • •EEA is the main approved commercial region for Ebvallo
  • •United Kingdom and Switzerland are also approved commercial markets
  • •United States is the key development market for tab-cel
  • •Commercial access depends on national reimbursement and payor decisions
  • •Manufacturing and distribution must support cross-border cell therapy logistics

Atara’s strategy is to convert its EBV T-cell platform into approved, off-the-shelf therapies for patients with serious...

01
U.S. development of tab-celshort-term

FDA approval is required before the company can commercialize its lead asset in the largest market.

02
Commercial execution for Ebvalloshort-term

Approved markets generate the company’s current commercialization opportunity and validate the platform.

03
Manufacturing scale-up and process robustnessmedium-term

Cell therapy economics and launch readiness depend on reproducible, compliant manufacturing.

04
Strategic alternatives reviewshort-term

A transaction could provide capital, partnership depth, or a path to maximize value if standalone execution remains difficult.

Atara’s business is exposed to the binary nature of biotechnology development, where regulatory setbacks or weak...

high

Regulatory failure or delay

The company cannot commercialize U.S. product candidates without FDA approval and must also satisfy foreign regulators for ex-U.S. sales.

Scope
tab-cel and future pipeline assets
Materiality
high
high

Manufacturing scale-up and supply-chain disruption

Cell therapy production depends on specialized raw materials, leukapheresis collections, and validated facilities; shortages or process failures can halt supply.

Scope
commercial supply and clinical trial material
Materiality
high
high

Reimbursement and market access uncertainty

Even approved therapies may face coverage denials, pricing pressure, or limited hospital adoption due to cost and resource constraints.

Scope
Ebvallo commercialization
Materiality
high
medium

Strategic alternatives may not succeed

Management is reviewing strategic alternatives, but there is no assurance a transaction will occur or create value.

Scope
corporate strategy
Materiality
medium
medium

Intellectual property and competitive pressure

Biotech value depends on patent protection and differentiation versus competing therapies and technologies.

Scope
platform and pipeline
Materiality
medium
Revenue recognition for commercialization services and transfer activities
Quarterly revenue volatility
Inventory classification and zero-cost inventory treatment
Gross margin and operating expense presentation
Clinical trial and manufacturing cost capitalization/expense timing
Operating loss and comparability
Stock-based compensation and employee-related accruals
Reported operating expenses

BioAtla, Inc.

BCAB · Biological Products, (No Diagnostic Substances)

Bicara Therapeutics Inc.

BCAX · Pharmaceutical Preparations

Aptevo Therapeutics Inc.

APVO · Pharmaceutical Preparations

Aprea Therapeutics, Inc.

APRE · Pharmaceutical Preparations

BriaCell Therapeutics Corp.

BCTX · Pharmaceutical Preparations

Arcellx, Inc.

Biological Products, (No Diagnostic Substances)

: 11/08/2026